Gary K. Lee - Feb 9, 2024 Form 4 Insider Report for Lyell Immunopharma, Inc. (LYEL)

Signature
/s/ Matthew Lang, as Attorney-in-Fact
Stock symbol
LYEL
Transactions as of
Feb 9, 2024
Transactions value $
$0
Form type
4
Date filed
2/13/2024, 08:22 PM
Previous filing
Nov 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LYEL Common Stock Award $0 +40K +314.96% $0.00 52.7K Feb 9, 2024 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYEL Stock Option (right to buy) Award $0 +400K $0.00 400K Feb 9, 2024 Common Stock 400K $1.80 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported transaction involved the Reporting Person's receipt of a grant of performance-based restricted stock units, subject to vesting upon the achievement of specified performance criteria. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F2 Includes 4,702 shares acquired on November 18, 2022, 6,205 shares acquired on May 18, 2023 and 1,793 shares acquired on November 17, 2023 under the Issuer's 2021 Employee Stock Purchase Plan.
F3 12.5% of the option shares shall vest on August 9, 2024, with the remaining option shares to vest in equal monthly installments over the following forty-two months.